Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 and obesity: fighting two pandemics with intermittent fasting

Kafi N. Ealey,1,3,* Joy Phillips,1,3 and Hoon-Ki Sung1,2,*

Obesity is strongly and independently associated with an increased risk of severe illness and death from coronavirus disease 2019 (COVID-19). The pathophysiological changes that result from elevated body weight lead to metabolic dysfunction, chronic inflammation, impaired immunological responses, and multisystem disorders, which increase vulnerability to severe illness from COVID-19. While vaccination strategies are under way across the world, the second and third waves of the pandemic, along with the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains, continue to threaten the stability of medical systems worldwide. Furthermore, evidence from previous pandemics suggests that vaccines are less effective in obese individuals than in their healthy-weight counterparts over the long term. Therefore, a consideration of lifestyle changes that can boost metabolic health and immunity is critical to reduce the risk of complications and severe illness from viral infection. In this review, we discuss the potential mechanisms linking excess body weight with COVID-19 morbidity. We also present evidence that intermittent fasting (IF), a dietary program that has gained popularity in recent years, may be an effective strategy to improve metabolic health and immunity and thus reduce the impact of obesity on COVID-19 morbidity and mortality.

Intersection of two pandemics

The COVID-19 pandemic has resulted in a major health crisis with devastating social and economic consequences. Studies from multiple clinical cohorts have shown that obesity is associated with increased complications, disease severity, and mortality on SARS-CoV-2 infection [1–3]. A risk assessment analysis of over 900 000 COVID-19 hospitalizations across the USA found that almost two-thirds of these hospitalizations were attributable to cardiometabolic conditions; namely, obesity, diabetes mellitus (DM), hypertension, and heart failure, with obesity accounting for 30% of hospitalizations [4]. COVID-19 patients with elevated body mass index (BMI) were reported to have significantly increased need for invasive mechanical ventilation, a robust proxy for severity of disease [3], were more likely to develop severe pneumonia, exhibited more severe lung pathological changes and injury, and had increased risk of mortality compared with non-obese patients (BMI <25 kg/m²), independent of age, sex, diabetes, and hypertension [1,2,5,6].

Unlike the rapid spread of COVID-19, the obesity pandemic has been slowly gaining momentum for decades. The global prevalence of obesity tripled between 1975 and 2016, and according to the World Health Organization over 650 million adults aged 18 years and over worldwide were obese in 2016 (https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight). Excess adipose tissue is a major source of proinflammatory factors that contribute to chronic systemic inflammation and a host of metabolic disturbances including type 2 DM (T2DM) [7]. Infection with SARS-CoV-2 elicits a wide spectrum of clinical responses (Box 1). Severe

Highlights

Obesity is a strong risk factor for severe illness and mortality from coronavirus disease 2019 (COVID-19) infection. Mechanisms linking obesity with severe COVID-19 include diabetes-associated hyperglycemia, inflammation, weakened immune function, and metabolic dysfunction.

Obese populations have a known history of poor response to vaccination and it is unknown whether this will also affect their vaccine-induced immunity to COVID-19. Therefore, it is important to implement dietary and lifestyle changes that potentially boost metabolic and immune health to mitigate the impacts of COVID-19.

Intermittent fasting (IF) is associated with weight loss, improved glucose homeostasis, metabolic health restoration, and strengthened immune responses.

Amid COVID-19 lockdowns, which are associated with more-sedentary lifestyles, the incorporation of IF may be a practical way to curb unhealthy eating habits, maximize healthy lifestyles, and improve mood and emotional well-being.

1Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, Canada
2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
3These authors contributed equally to this work

*Correspondence: kafi.ealey@sickkids.ca (K.N. Ealey) and hoon-ki.sung@sickkids.ca (H.-K. Sung).
complications of COVID-19 infection and cytokine storm are more pronounced in individuals with elevated BMI and diabetes [2,8], suggesting that obesity-associated inflammation and metabolic dysfunction exacerbate the severity of illness, thus culminating in the dangerous intersection of two global pandemics.

Currently, a number of COVID-19 vaccine candidates have undergone regulatory approval and are being used for vaccination. However, there remain barriers to achieving herd immunity, which is estimated to require that 60–70% of the population achieve immunity [9]. Factors such as vaccine hesitancy, manufacturing delays, distribution disparities, and the emergence of new, more transmissible SARS-CoV-2 variants that may be resistant to vaccines increase the potential for continued outbreaks [9]. Furthermore, obese populations have a known history of poor response to vaccination [10,11]. An unhealthy metabolic profile, including elevated baseline levels of proinflammatory cytokines and hyperglycemia, is significantly correlated with a dysfunctional immune response to COVID-19 [12,13]. Therefore, now more than ever, the world could benefit from the implementation of lifestyle changes that boost metabolic and immune health to mitigate the impacts of COVID-19.

In this review, we present an overview of the relationship between obesity, adiposity, DM, and COVID-19 severity. We also propose a lifestyle regimen that incorporates IF (Box 2) as a promising strategy to improve metabolic health and immune function, potentially reducing the risk of severe illness from COVID-19. Finally, we offer our perspectives on some of the unique benefits and challenges of adopting IF during a global pandemic.

Hyperglycemia and COVID-19 pathogenesis

Diabetes, a common comorbidity of COVID-19, is associated with a higher risk of excessive uncontrolled inflammatory responses, higher computerized tomography (CT) imaging scores indicating SARS-CoV-2 pneumonia, an increased likelihood of mechanical ventilation, and a shorter duration of survival, even after adjusting for other comorbidities (e.g., age, sex, hypertension, cardiovascular disease) [14–16]. Studies point to hyperglycemia, resulting from poor glycemic control, as a driver of COVID-19 progression and poor prognosis [17–19]. In one large retrospective, multicenter study of over 7000 patients with COVID-19 in Wuhan, China, among a cohort with COVID-19 and T2DM, individuals with well-controlled blood glucose exhibited significant reductions in adverse outcomes, major organ injuries, all-cause mortality, and overall comorbidities compared with those with poor glycemic control [18]. In other studies, elevated
Box 2. Managing obesity through diet and exercise

Restriction of energy intake has beneficial effects on human health, including extended longevity, disease protection, and delayed aging [74,98]. To address the difficulty of adhering to conventional, calorically restrictive weight-loss regimes, IF has gained popularity as an effective and practical alternative. Recently, IF has been shown to be an effective intervention for body weight regulation and glycemic control in many preclinical and clinical studies [59–61,64,65]. Unlike CR, which is defined as a chronic 20–40% reduction of total caloric intake without any changes in meal frequency or timing [74], IF involves recurring periods of fasting, alternating with AL food consumption [66]. Subtypes of IF are described in Figure I.

Regular exercise of moderate to high intensity has been shown to reduce body weight and fat mass; however, evidence suggests that exercise alone generally leads to modest or clinically insignificant weight loss [99]. One trial assessed the effects of combining IF with endurance exercise on 3 days per week for 12 weeks in obese adults [100]. While body weight and BMI were reduced in both groups, the combination of both interventions resulted in a superior reduction in these parameters [100]. Interestingly, fat mass significantly decreased in the IF and combination group but not the exercise group, potentially highlighting the limitations of exercise alone as an antiobesity approach [100]. By contrast, one meta-analysis found that combining IF with resistance-training exercise had either small or inconsistent effects on decreasing body and fat mass compared with resistance training alone [101], indicating a need for further studies to validate the advantages of combining exercise with IF.

As recent evidence suggests that physical activity is protective against severe COVID-19 outcomes [102], a lifestyle that incorporates both physical activity and dietary intervention is likely to be an ideal approach to mitigating the impacts of COVID-19. However, during the COVID-19 pandemic, evidence suggests that social distancing has increased barriers to participation in physical activity [83]. One benefit of IF is that it is a zero-cost and -time approach to managing weight, whereas exercise generally requires time, resources, and access to facilities—barriers associated with inactivity [103]. Thus, while exercise and IF are both attractive options for managing weight, IF may be a more pragmatic approach for some, particularly during the global pandemic. See Figure I for a description and comparison of weight-loss approaches.

---

### Comparing healthy lifestyle approaches

| Approach | Description | ↓ Weight, BMI and fat mass | Improves glucose homeostasis | Zero time commitment/financial cost | Nonrestrictive meal timing | Does not require reduced energy intake |
|----------|-------------|---------------------------|-----------------------------|-----------------------------------|---------------------------|---------------------------------------|
| CR       | Caloric restriction Chronic 20–40% reduction of total caloric intake | ✔️ | ✔️ | ✔️ | ✔️ | ✗ |
| ADF      | Alternate-day fasting IF that involves alternating ad libitum eating days with fasting days | ✔️ | ✔️ | ✔️ | ✗ | ✔️ |
| TRF      | Time-restricted feeding IF that restricts food consumption to a discrete daily time window during the active phase | ✔️ | ✔️ | ✔️ | ✗ | ✔️ |
| Exercise | Exercise A structured form of physical activity; examples include aerobic exercise, resistance training and high-intensity interval training | ✔️ | ✔️ | ✗ | ✔️ | ✔️ |

*CR may involve preparation/purchase of diet-friendly foods.*

---

Figure I. Comparing healthy lifestyle approaches. Lifestyle interventions that support the management of obesity and promote metabolic health include caloric restriction (CR), alternate-day fasting (ADF), time-restricted feeding (TRF), and physical exercise. These interventions have all been shown to improve body composition and glucose homeostasis [56,63,98,99]. Unlike ADF and TRF [subtypes of intermittent fasting (IF)], exercise regimens require time and, often, financial resources to implement. Depending on the circumstances, this can be a burden associated with CR regimens as well. Moreover, energy intake is chronically restricted with CR, creating unique challenges for long-term adherence. A major benefit of ADF and TRF is that overall energy intake is not restricted, although this is often an unintended consequence of these regimens [59]. Meal timing is, however, restricted with IF, posing distinct adherence challenges. Figure created with BioRender.com. Abbreviation: BMI, body mass index.
fasting blood glucose at the time of admission was associated with longer hospitalization and higher levels of in-hospital complications and mortality [20–22]. Thus, fasting blood glucose at the time of admission was reported to be the best predictor of radiographic imaging of SARS-CoV-2 [21] and was an independent predictor of mortality, regardless of past medical history of diabetes [20–22].

**Mechanisms linking impaired glucose metabolism with the severity of COVID-19**

Increased cellular glucose metabolism may be a key link to the severity of COVID-19 (Figure 1). One study showed that increased hexosamine biosynthesis, a glucose metabolic pathway that is activated by influenza infection, led to the O-GlcNAcylation of interferon regulatory factor-5 (IRF-5), which is critical for the induction of cytokine storms during viral infections [23]. Similarly,
patients with influenza had more O-GlcNAcylation of IRF-5 and higher blood glucose levels, which were tightly correlated with levels of circulating inflammatory cytokines [23]. Thus, interfering with glucose metabolism and/or glucose utilization pathways may prevent deadly cytokine storms. The expression of IRF-5 and its related proinflammatory cytokines was associated with the severity and prognosis of community-acquired pneumonia influenza virus infection [24]. Furthermore, IRF-5, a marker of metabolic inflammation, has been reported to be significantly elevated in the subcutaneous adipose tissues of diabetic obese patients compared with diabetic lean/overweight individuals [25] and is implicated in macrophage polarization toward a proinflammatory M1 phenotype [25,26] (Figure 1). Inhibition of IRF-5 signaling pathways has been proposed as a potential therapy for severe COVID-19 [27].

Increased glycolysis exacerbated by elevated glucose levels was shown to promote SARS-CoV-2 replication and proinflammatory cytokine secretion in monocytes [8]. Accordingly, monocytes isolated from obese diabetic patients who were infected with SARS-CoV-2 exhibited increased viral load compared with monocytes from healthy controls, providing further evidence that hyperglycemic individuals may be more susceptible to severe COVID-19 [8]. Furthermore, mitochondrial reactive oxygen species production, induced by SARS-CoV-2 infection, led to the stabilization of hypoxia-inducible factor-1α (HIF-1α), which upregulates glycolytic genes. Thus, uncontrolled hyperglycemia may create a permissive environment for SARS-CoV-2 by increasing glycolytic flux [8].

The relationship between expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, and COVID-19 pathogenesis is unclear (Box 3); however, hyperglycemia could lead to increased glycosylation of ACE2, which is thought to be important for its function and may facilitate viral entry [28,29]. Expression of glycosylated ACE2 rather than total ACE2 is associated with viral binding and fusion in the lung [30].

Box 3. Tissue ACE2 expression and relationship to COVID-19 pathogenesis

SARS-CoV-2 gains entry into host cells through the binding of its envelope spike protein to the human cell receptor ACE2 [104]. The serine protease transmembrane serine protease 2 (TMPRSS2) is essential for ACE2-receptor-mediated binding and viral entry [104]. ACE2 is expressed ubiquitously, with its expression highest in the digestive system, specifically ileal epithelial cells, as well as in the lungs, kidneys, heart, bladder, and adipose tissue [48]. In the lungs, alveolar type II pneumocytes (AT2 cells) and transient bronchial secretory cell populations coexpress ACE2 and TMPRSS2 and are suspected to be the main targets for SARS-CoV-2 infection [105].

ACE2 is an important negative regulator of the renin-angiotensin system (RAS) [106]. Signaling of angiotensin II (AngII) through the AngII type 1 receptor promotes vasoconstrictive responses [106]. ACE2 catalyzes the cleavage of AngII, producing angiotensin 1-7, a vasodilator associated with beneficial regulation of blood pressure homeostasis [106].

Adipose tissue, where ACE2 is highly expressed and is even further upregulated in obesity, has been reported to be a reservoir for SARS-CoV-2 [107]. The relationship between adipocyte expression of ACE2 and the pathogenesis of COVID-19, however, is unknown. ACE2 expression was significantly upregulated in lung tissue from obese mice compared with lean mice and both ACE2 and TMPRSS2 were increased in human lung epithelial cells from obese subjects compared with non-obese individuals [108], which could enhance the entry of SARS-CoV-2 into the cell. However, SARS-CoV-2 infection downregulated the expression of ACE2, a process theorized to contribute to lung injury and increase disease severity [104,109]. Based on observations that conditions reported to be strongly associated with severe symptoms of COVID-19 infection show a degree of ACE2 deficiency, it has been suggested that the downregulation of ACE2 induced by the entry of SARS-CoV-2 into the host cell may be particularly detrimental in individuals with a baseline deficiency of ACE2, who may have a more marked imbalance of the RAS system [104]. Therapies that can increase baseline ACE2 expression may reduce the exaggerated imbalance of the RAS system on COVID-19 infection. Notably, in mice a 4-week IF treatment mitigated HFD-induced increases in systolic blood pressure and increased left ventricular expression of ACE2 associated with beneficial remodeling of cardiac tissue [110]. Furthermore, human studies have also reported positive benefits of IF on hypertension [59,63]. Evidently, the relationship between tissue ACE2 expression and susceptibility to SARS-CoV-2 infection as well as COVID-19 pathogenesis is complex and warrants further investigation.
**Obesity, immunity, and COVID-19**

The accumulation of excess adipose tissue leads to a state of chronic inflammation characterized by a phenotypic shift from an anti-inflammatory to a proinflammatory metabolic milieu with increased secretion of proinflammatory cytokines and dysfunctional immune responses that could play a major role in predisposing individuals to severe COVID-19 [7,31] (Figure 2). At least one-third of circulating interleukin (IL)-6, a central driver of inflammation and a strong clinical predictor of disease severity and mortality resulting from COVID-19 infection, is estimated to come from adipose tissue [32,33]. Compared with patients with nonsevere COVID-19, patients with severe COVID-19 had significantly higher baseline circulating IL-6 levels on admission, which increased over the course of the disease, suggesting that baseline circulating IL-6 may be a prognostic marker of COVID-19 [13]. Similarly, high serum IL-6, IL-8, and tumor necrosis factor alpha (TNF-α) at baseline (i.e., at the time of hospitalization) are strong and independent predictors of patient survival [12].
Leptin in COVID-19 pathogenesis

Circulating leptin is well known to be elevated in obese individuals [7,31]. High levels of circulating leptin and selective leptin resistance have been implicated in impaired immune response to viral infection, diminished vaccine response, and chronic low-grade inflammation [34]. Leptin could be a key contributor to acute respiratory distress syndrome (ARDS) and cytokine storms during the advanced stages of COVID-19. Obese mice challenged with H1N1 infection developed more extensive lung inflammation and damage as well as enhanced proinflammatory cytokine expression compared with lean mice [35]. Importantly, leptin inhibition with an antileptin antibody improved the cytokine profiles and survival rates of these obese mice [35]. In one cross-sectional study of intensive care unit (ICU) patients in The Netherlands, patients with COVID-19 had significantly higher serum leptin levels compared with BMI-matched controls (who did not have COVID-19) [36]. Circulating leptin, together with IL-6, CXCL10, and TNF-α, has been reported to be significantly associated with severe COVID-19 illness and inflammatory monocyte activation [37].

Obesity impairs vaccine responses

In a recent study, obese mice inoculated with a human influenza virus showed increased disease severity and viral spread [38]. Moreover, viruses from obese hosts had increased replicative ability, genetic diversity, and virulence [38]. Memory T cell responses, which are critical for conferring immunological memory and serve as major components of vaccination strategies, are impaired in obese individuals [39,40]. Among adults who received influenza vaccines, those who were obese were twice as likely to develop influenza or influenza-like disease as healthy-weight counterparts, despite having similar antibody titers 1 month after influenza vaccination [10]. In addition, CD4+ and CD8+ T cell activation and cytotoxicity, which correlate with disease protection, were defective in cells taken from obese individuals compared with those taken from healthy individuals [10,11]. Obesity was also associated with attenuated influenza vaccine responses, reduced circulating switched memory B cells, and increased proinflammatory late/exhausted dysfunctional B cells [41]. Leptin resistance may be implicated in these responses. Downregulation of the leptin receptor (LEPR) and the upregulation of suppressors of cytokine signaling (e.g., SOCS1, SOCS3), which contribute to leptin resistance, led to decreased maintenance of influenza-specific CD8+ effector memory T cells in the lungs of a diet-induced obese mouse model 84 days post-influenza infection [39].

As COVID-19 vaccines continue to gain widespread regulatory approval globally, these data are critically relevant to the overall long-term success of COVID-19 vaccine strategies. According to published clinical trial results, Pfizer-BioNTech’s COVID-19 vaccine was 95% effective in preventing COVID-19 disease, including in people with obesity (BMI ≥30 kg/m²), who comprised one-third of participants in the clinical trial [42]. Similarly, in the Moderna vaccine trial, vaccine efficacy in participants with severe obesity (BMI ≥40 kg/m²) was comparable (>90%) with that in other participants at low risk [43]. Thus, the evidence suggests that this higher-risk group responds extremely well to the vaccine in the short-term. However, it remains unclear how well obese individuals maintain long-term SARS-CoV-2 vaccine-induced immunity (Figure 2). One recent study, published as a preprint, reported that the Pfizer vaccine was less effective in people with obesity, as healthcare workers with obesity had a significantly lower antibody titer in response to vaccination than those classified as normal weight [44]. Further, compared with lean COVID-19 patients, obese patients were reported to have significantly lower serum levels of SARS-CoV-2-specific IgG antibodies, which negatively correlated with BMI and serum levels of proinflammatory markers [45]. These data, while preliminary, indicate that the dysfunctional immune responses in obesity may extend to COVID-19.
Gut health and COVID-19
Aside from the lungs, the gastrointestinal (GI) system is likely to be another target of SARS-CoV-2, as clinical presentations of GI symptoms in COVID-19 patients have been well documented [46] and viral fecal RNA is known to be present in a significant proportion of COVID-19 patients [47]. Relative to other human tissues, ACE2 is highly expressed in small intestinal enterocytes [48]. In addition to the potential role of the gut as a direct entry point for SARS-CoV-2, poor gut health could have important implications for the severity and outcomes of COVID-19. Gut barrier dysfunction and an altered gut microbiome are hallmark changes associated with obesity [49]. Changes in the composition of the gut microbiome have been postulated to play a role in abnormal immune responses and the severity of COVID-19 [50,51], although substantial evidence for this is forthcoming. Constant interactions between the mammalian host and its commensal gut microbes are crucial for proper immune system development, maintenance, and function [52]. While gut dysbiosis has been widely observed in a number of chronic inflammatory conditions, including obesity, dramatic dysbiosis has also been observed in critically ill patients and is hypothesized to be involved in the pathogenesis of ARDS and sepsis [53]. Accordingly, patients positive for COVID-19 exhibited significant gut dysbiosis, with decreased microbiota diversity and increased opportunistic pathogens that persisted even after clearance of the virus [50,54]. Another study found that COVID-19 patients had significantly altered microbiomes compared with non-COVID-19 controls and that the microbiota composition was associated with disease severity [51]. Given that persistent dysbiosis is frequently observed in COVID-19 patients, improving the parameters of the gut microbiome could ameliorate long-term complications and accelerate recovery from COVID-19 [51].

Increased gut barrier permeability in individuals with obesity and T2DM is associated with leakage of bacteria and bacterial products into the circulation, which leads to metabolic endotoxemia, a major contributor to inflammation [49,55]. It is postulated that enhanced synergistic interactions of bacterial and viral pathogens can potentiate lung injury, suggesting a mechanism by which gut barrier dysfunction in obesity and T2DM may worsen the severity of COVID-19 [49].

IF improves metabolic health
Compelling evidence from human and animal studies indicates that IF regimens (Box 2) promote numerous metabolic benefits, including weight loss, reduced adiposity, and improved glucose homeostasis (Figure 3) [56]. One group used a mobile application to track the eating patterns of healthy adults and found that over half of the individuals exhibited erratic eating patterns, consuming food for an average of 15 h/day [57]. Shifting overweight individuals to a time-restricted feeding (TRF) regimen in which they consumed food within a daily 10–11-h window resulted in body weight reductions [57]. Furthermore, restricting daily food intake to an 8–10-h duration resulted in significant reductions in body weight and adiposity and improved glucose tolerance in overweight/obese adults [58,59]; this intervention also reduced abdominal adiposity in individuals who exhibited one or more components of the metabolic syndrome [60]. Similarly, 4-h and 6-h TRF regimens were found to correspond to reductions in body weight, fat mass, markers of oxidative stress, and fasting insulin as well as improved insulin sensitivity in a group of obese individuals [61]. A short, 4-day 6-h early TRF regimen decreased mean 24-h glucose levels in overweight adults [62]. One study reported positive metabolic effects of IF that were independent of weight reduction. In men at risk for T2DM, 5 weeks of 6-h early TRF (in which all calories are consumed early in the day) resulted in improvements in insulin sensitivity, reduced markers of oxidative stress, and reduced blood pressure even in the absence of weight reduction and without change in overall energy expenditure compared with individuals who consumed calories over a 12-h period [63]. Similarly, isocaloric IF improved glucose tolerance in genetically obese mice in the absence of weight or fat mass reduction [64].
Mice consuming an isocaloric 2:1 IF diet (2 days feeding, 1 day fasting) for 16 weeks were protected from diet-induced obesity and exhibited improved glucose homeostasis and increased insulin sensitivity compared with ad libitum (AL)-fed mice [65]. In mice consuming various obesogenic diets, limiting food access to 8–9 h during the active phase prevented body weight gain and fat accumulation, reversed pre-existing obesity and glucose intolerance, and reduced markers of adipose tissue inflammation in obese mice, regardless of diet and caloric intake [66].

Glucose-lowering dipeptidyl-peptidase-4 (DPP4) inhibitors, which are widely used in the treatment of T2DM, have been proposed as a strategy to offset the severity of COVID-19 infection [67,68]. However, evidence for this application is scant and more studies on this intervention are needed. Notably, DPP4 plays a role in glucose and insulin metabolism and is positively correlated with adipocyte inflammation and insulin resistance [69]. DPP4 inhibitors act as agonists of the gut hormone glucagon-like peptide 1 (GLP-1) receptor, leading to increased circulating GLP-1 levels, improved pancreatic islet responses, and enhanced glucose homeostasis [69] (Figure 3). In obese mice, IF increased the secretion of GLP-1 [64], which could improve insulin sensitivity by essentially mimicking the function of DPP4 inhibitors. Taken together, these findings suggest that through improvements in glucose homeostasis and adiposity, IF and TRF diet regimens could lower the risk of severe COVID-19 complications.

Figure 3. Intermittent fasting (IF) and glucose homeostasis. Evidence from both preclinical and clinical studies indicates that various IF regimens improve glucose homeostasis and insulin sensitivity, even in the absence of weight loss or no change in overall energy expenditure [63,65]. We propose that glycemic control by IF could contribute to lowering the risk of severe complications from coronavirus disease 2019 (COVID-19). Figure created with BioRender.com. Abbreviation: GLP-1, glucagon-like peptide 1.
IF reduces inflammation
Evidence for the prognostic role of inflammatory factors and defective immune cells in weakened responses to SARS-CoV-2 infection raises the possibility that strategies to modulate these circulating factors or boost memory T cells could potentially improve the immune response to COVID-19. Concomitant with improvements in glucose homeostasis, some studies have also reported reductions in inflammatory cytokines with IF [70,71], although others report no change in these markers despite other metabolic improvements [58,61,63]. Ramadan fasting, observed by millions of Muslims globally, involves daily diurnal IF for a period of 12–19 h. Both during and outside the month of Ramadan, IF has been shown to decrease circulating TNF-α, IL-1β, and IL-6 levels compared with non-fasting baseline levels, accompanied by significant weight loss and improved glucose metabolism [71,72]. Similarly, intermittent caloric restriction (CR) in rodents significantly reduced circulating and adipose tissue levels of IL-6, TNF-α, insulin-like growth factor 1 (IGF-1), and leptin compared with AL-fed mice [70]. Fasting and IF strategies have been shown to lower leptin levels [66,70] and correct immune defects associated with aging and other conditions characterized by dysregulated leptin signaling, including obesity, metabolic syndrome, and autoimmunity [65,73,74].

In a mouse model of a chronic inflammatory disease, a 6-week alternate-day fasting (ADF) protocol prior to disease onset led to reduced proinflammatory monocyte numbers during disease development and downregulated the expression of the proinflammatory genes TNF-α, IL-1β, CXCL2, and CXCL10 in monocytes compared with an AL feeding group [75]. In addition, short-term fasting reduced monocyte numbers and the frequency of circulating and tissue-resident proinflammatory monocytes in humans and mice, respectively [75]. A CR diet in mice led to the homing of memory T cells to a bone marrow (BM) niche from which these cells were rapidly mobilized during secondary infection, providing enhanced protection against subsequent microbial challenge and prolonging host survival compared with AL-fed mice [76]. Given the similar responses to the CR and IF regimens, it is plausible that IF could also promote BM storage of memory T cells. Multiple cycles of a prolonged 48-h fast led to the renewal and regeneration of hematopoietic stem cells and reduced circulating IGF-1 levels, suggesting that cycles of fasting and refeeding can alter the frequency and composition of circulating immune cells infiltrating peripheral tissues and lead to a reset of the immune system [77]. These findings raise the possibility that IF could potentially reverse immune deficits in obese individuals, thus serving as a preventive, disease-mitigating approach to lower the risk of COVID-19 complications and potentially increase vaccine success (Figure 2).

IF effects on autophagy
As recently reviewed, IF may also boost the host immune system by activating pathways involved in autophagy [78]. While obesity, hypernutrition, and associated lipotoxicity have been associated with the attenuation of autophagic processes [79], CR regimens enhance autophagy through AMP-activated protein kinase negative regulation of mammalian target of rapamycin (mTOR) [78]. Autophagy improves the body’s ability to handle cellular stress and primes the host immune system by strengthening the survival and responses of T and B cells as well as antigen-presenting cells, which could prevent severe complications of SARS-CoV-2 infection [78]. TRF was reported to increase markers of autophagy in overweight humans [62] and decreased oxidative stress [61,63].

IF improves gut health
Much of what we know about the effects of IF on the gut comes from animal studies. Compared with AL-fed controls, a fasting mimicking diet (FMD) has been shown to increase the diversity of
the gut microbiota and decrease the Firmicutes:Bacteroidetes ratio; the resulting phenotype is consistent with that of a healthy, lean gut [80]. At the genus level, the FMD group showed decreases in several genera that were positively correlated with fasting blood glucose as well as increases in genera that were negatively correlated with fasting glucose [80]. In a separate study in HFD-induced obese mice, compared with AL-fed controls, ADF-fed mice showed significant changes in gut microbiota composition and significant metabolic improvements that were abolished in microbiota-depleted mice [81]. Finally, IF has been shown to reduce widespread systemic inflammation in a gut-dependent manner [73]. Taken together, these studies suggest that IF-mediated benefits for gut health could improve metabolic and immune health, thus ameliorating outcomes for COVID-19 patients.

Concluding remarks and future perspectives

As we have reviewed, obesity and T2DM increase the incidence of severe complications, cytokine storms, and mortality from COVID-19. Disparities in vaccine distribution, vaccine hesitancy, and the emergence of SARS-CoV-2 variants are barriers to achieving population immunity, increasing the potential for continued outbreaks, hospitalizations, and mortality resulting from COVID-19 illness [9]. With obesity on the rise and potential for continued COVID-19 outbreaks globally, it is more important than ever to develop strategies that could reduce inflammation, improve glycemic control, and boost immune health. Naturally, this necessitates curbing overnutrition and maladaptive eating habits that lead to poor metabolic health. We have highlighted the numerous beneficial effects of IF on adiposity, metabolic health, glucose homeostasis, the antiviral immune response, long-term immunity, inflammatory markers, and the gut. One critical question remains surrounding the long-term efficacy of COVID-19 vaccination in obese individuals (see Outstanding questions), as memory T cell activation and responses to vaccination are blunted in this population [10,11,44]. In a recent study, an obesity-related microenvironment in mice promoted the emergence of more virulent pathogenic influenza virus strains that induced greater disease severity in lean hosts [38]. This raises the intriguing possibility that obese metabolic phenotypes could impact future generations of novel COVID-19 variants.

IF in the time of COVID?

As a result of the COVID-19 pandemic, billions of individuals continue to practice various measures of social distancing and imposed lockdowns. This has resulted in increased sedentary lifestyles and prolonged periods of social isolation, which have been reported to be detrimental to physical and mental health [82,83]. Globally, eating habits have changed drastically during the pandemic [84–86]. Generally, more time spent cooking and eating at home, less time spent exercising, boredom, and stress have all given rise to overeating and mindless snacking [85–87]. Pandemic-induced lifestyle changes have also led some to increase their focus on healthy eating and seek out strategies to boost their immunity and health [84,87]. Given the current social climate, with limited opportunities for physical activity, dietary changes such as IF regimens may be a practical way to curb unhealthy eating habits and maximize metabolic health during the pandemic. In particular, TRF regimens have been associated with decreased feelings of hunger throughout the day, curbing non-hungry snacking and mindless eating [57,63]. Furthermore, IF is also associated with improvements in mood and emotional well-being [88,89] (Figure 4, Key figure). We propose that TRF or IF may be more sustainable than traditional diets because it allows individuals to maintain their usual diets with shorter eating durations. In many studies, reducing the duration of eating each day led to unintentional decreases in caloric intake, leading to weight loss and associated metabolic benefits [57,59]. However, IF has been shown to have positive metabolic consequences, such as improved glucose homeostasis, even in the absence of weight reduction and/or no changes in overall energy expenditure [83–85]. It must be cautioned that most of the evidence for these findings are from small controlled clinical trials, and an absence of significant effects of TRF on weight and metabolic parameters has also been reported [90]. Importantly, IF regimens

Outstanding questions

Due to the relative speed at which COVID-19 vaccines were developed, tested, and approved, there are currently no long-term data on their efficacy in obese populations. Will long-term immunity from COVID-19 vaccination be hampered in obese individuals, as has been observed for other vaccines? We predict that obese individuals would experience quicker declines in vaccine-induced immunity than lean individuals, making this population at higher risk for infection and resulting in negative consequences for the overall success of COVID-19 vaccination programs worldwide.

Most clinical trials of IF have examined small samples of participants over relatively short periods of time. Evidence on whether adherence can be sustained in the long term is forthcoming. Furthermore, much of the evidence for the impact of IF and/or CR on adaptive immunity, memory T cells, immune system reset, and gut health, which are critical parameters of antiviral immunity, have come from preclinical studies. This raises the question of whether IF strategies can impact immunopathological mechanisms specific to SARS-CoV-2. There is a critical need for studies testing the role of dietary strategies, including IF, in improving antiviral immunity and reducing the severity of COVID-19.

In this review, we provide evidence that IF may help to reduce the risk of severe COVID-19 in obese, diabetic, and/or metabolically unhealthy individuals. However, it is less clear whether these putative benefits extend to lean, metabolically healthy individuals. Given that the risk of developing severe COVID-19 symptoms is greatly increased in older individuals as well as in those with weakened immune systems and pre-existing conditions, it is conceivable that IF could worsen disease conditions in these individuals who may already be frail and vulnerable to nutritional deficiencies. Ultimately, further investigation is needed to clarify whether the putative benefits and safety profile of IF are dependent on the host’s caloric intake and/or baseline fat mass and metabolic health.
have not been addressed in relation to COVID-19 illness (see Outstanding questions). Ultimately, as outlined in Box 2, a combination of nutritional lifestyles and physical activity are likely to be most effective.

Finally, there are some concerns about whether IF strategies are appropriate for everyone. It is possible that certain dietary regimens involving reduced caloric intake could harness immunosuppressive effects, thus weakening the anti-SARS-CoV-2 immune response [91]. There are also limited reports on the effects of IF in elderly populations. Although IF has been shown to have
physical and mental benefits in an elderly population (>65 years of age) [92], caution must be exercised when recommending fasting strategies to improve health for the elderly and those with weakened immunity (see Outstanding questions).

In conclusion, while IF is an exciting and growing field of investigation, further research efforts are needed to establish the effects of IF on antiviral immunity, particularly in the context of COVID-19. Given that IF has shown profound promise in improving metabolic health, we argue that now is a better time than ever to adopt this healthy lifestyle strategy (Figure 4).

Acknowledgments
We thank Lauren Pikel, Christy Yeung, and Irisa Qianwen Shi for critical reading of the manuscript and helpful suggestions and Irisa Qianwen Shi for help creating figures. This research was funded by the Canadian Institutes of Health Research (CIHR, PJT-162083) of Canada, a Sun Life Financial New Investigator Award, and a Reuben and Helene Dennis Scholar Award of the Banting and Best Diabetic Centre (BBDC), University of Toronto.

Declaration of interests
None are declared.

Author contributions
K.N.E., J.P., and H.K.S. conceived and designed the research. All authors agreed to the final version of the manuscript.

References
1. Gao, M. et al. (2021) Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 9, 350–359
2. Kang, Z. et al. (2020) Obesity is a potential risk factor contributing to clinical manifestations of COVID-19. Int. J. Obes. (Lond.) 44, 2479–2485
3. Simonnet, A. et al. (2020) High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 28, 1195–1199
4. O’Hearn, M. et al. (2021) Coronavirus disease 2019 hospitalizations attributable to cardiometabolic conditions in the United States: a comparative risk assessment analysis. J. Am. Heart Assoc. 10, e019559
5. Hendren, N.S. et al. (2021) Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation 143, 115–114
6. Guerson-Gil, A. et al. (2021) Sex-specific impact of severe obesity in the outcomes of hospitalized patients with COVID-19: a large retrospective study from the Bronx, New York. Eur. J. Clin. Microbiol. Infect. Dis. Published online May 6, 2021, https://doi.org/10.1007/s10096-021-04260-z
7. Alaor, P.C. et al. (2021) Adipocyte inflammation and pathogeneses of viral pneumonia: an overlooked contribution. Microsoma Immunitat. Published online May 6, 2021, https://doi.org/10.1038/s41356-021-00404-8
8. Codo, A.C. et al. (2020) Elevated glucose levels favor SARS-CoV-2 infection and monocYTE response through a HM-1/ glycolysis-dependent axis. Cell Metab. 32, 427–436.e435
9. Aschwanden, C. (2021) Five reasons why COVID herd immunity is probably impossible. Nature 591, 520–522
10. Neklich, S.D. et al. (2021) Increased risk of influenza among vaccinated adults who are obese. Int. J. Obes. (Lond.) 41, 1304–1309
11. Paich, H.A. et al. (2013) Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity (Silver Spring) 21, 2577–2586
12. Del Valle, D.M. et al. (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1635–1643
13. Laguna-Goya, R. et al. (2020) IL-6-based mortality risk model for hospitalized patients with COVID-19. J. Allergy Clin. Immunol. 146, 785–797.e709
14. Carlu, B. et al. (2020) Phenotypic characteristics and prognosis of Inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 63, 1500–1515
15. Guo, W. et al. (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 36, e3219
16. Yan, Y. et al. (2020) Clinical characteristics and outcomes of patients with severe Covid-19 with diabetes. BMJ Open Diabetes Res. Care 8, e001343
17. Bode, B. et al. (2021) Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J. Diabetes Sci. Technol. 14, 813–821
18. Zhu, L. et al. (2021) Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31, 1069–1077.e1063
19. Smith, S.M. et al. (2021) Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J. Med. Virol. 93, 439–445
20. Caramas-Sanchez, F.J. et al. (2021) Admission hypercyrenaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMIC-COVID-19 Registry. Ann. Med. 52, 109–116
21. Iacobelli, G. et al. (2020) Admission hypercyrenaemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res. Clin. Pract. 164, 108185
22. Wang, S. et al. (2020) Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multicentre retrospective study. Diabetologia 63, 2102–2111
23. Wang, G. et al. (2020) O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5. Sci. Adv. 6, eaaz7086
24. Wang, X. et al. (2018) Expression levels of interferon regulatory factor 5 (IRF5) and related interferon cytokines associated with severity, prognosis, and causative pathogen in patients with community-acquired pneumonia. Med. Sci. Monit. 24, 3620–3630
25. Sinhar, S. et al. (2020) Enhanced adipsic adipose expression of interferon regulatory factor-5 (IRF5) associates with the signatures of metabolic inflammation in diabetic obese patients. Cells 9, 730
26. Dalmaz, E. et al. (2015) IRF5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat. Med. 21, 610–618
27. Styly, N. (2021) Involvement of interleukin-1 receptor-associated kinase 4 and interleukin-4 receptor alpha in the immunopathogenesis of SARS-CoV-2 infection: implications for the treatment of COVID-19. Front. Immunol. 12, 638446
28. Walls, A.C. et al. (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 261-292.e269
29. Mehdirpour, A.R. and Hummer, G. (2021) Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proc. Natl. Acad. Sci. U. S. A. 118, e2110042118
30. Brusky, A. (2020) Hyperglycemia, hydroxycortizone, and the COVID-19 pandemic. J. Med. Virol. 92, 770–775
31. Porsche, C.E. et al. (2021) Obesity results in adipose tissue T-cell exhaustion. JOC Insight 6, e139793
32. Chen, G. et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629
33. Mohamed-Ali, V. et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196-4200
34. Ali, D. et al. (2018) Emergence of leptin in infection and immunity: scope and challenges in vaccines formulation. Front. Cell. Infect. Microbiol. 8, 147
35. Zhang, A.J. et al. (2013) Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J. Infect. Dis. 207, 1270-1280
36. van der Voort, P.H.J. et al. (2020) Leptin levels in SARS-CoV-2 infection related respiratory failure: a cross-sectional study and a pathophysiological framework on the role of fat tissue. Hormetica 6, e04660
37. Wang, J. et al. (2021) Leptin correlates with monocytosis activation and severe condition in COVID-19 patients. J. Leukoc. Biol. Published online January 6, 2021. https://doi.org/10.1002/JLB.5HI1020-704R
38. Honce, R. et al. (2021) Obesity-related microenvironment promotes emergence of virulent influenza virus strains. mBio 11, e03341-19
39. Karlsson, E.A. et al. (2010) Diet-induced obesity in mice reduces the maintenance of influenza-specific CD8+ memory T cells. J. Nutr. 140, 1691-1697
40. Rebello, J. et al. (2018) Obesity-induced changes in T-cell metabolism are associated with impaired memory T-cell response to influenza and are not reversed with weight loss. J. Infect. Dis. 219, 1652–1661
41. Frasca, D. et al. (2016) Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring) 24, 615-625
42. Polack, F.P. et al. (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2033-2051
43. Baden, L.R. et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine in adults. N. Engl. J. Med. 385, 423–432
44. Pellini, R. et al. (2021) Obesity may hamper SARS-CoV-2-specific vaccine. medRxiv Published online February 25, 2021. https://doi.org/10.1101/2021.02.24.21251664
45. Frasca, D. et al. (2021) Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One 16, e0245424
46. Mao, R. et al. (2020) Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 667–678
47. Wang, W. et al. (2020) Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 323, 1843–1844
48. Li, M.Y. et al. (2020) Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 9, 45
49. Kruglikov, I.L. et al. (2020) Obesity and diabetes as comorbidities for COVID-19: underlying mechanisms and the role of viral-bacterial interactions. Effie 9, e61330
50. Gu, S. et al. (2020) Alterations of the gut microbiota in patients with coronavirus disease 2019 or HIV1 infection. Clin. Infect. Dis. 71, 2696-2708
51. Yeo, Y.K. et al. (2021) Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 908-916
52. Belkaid, Y. and Harrison, O.J. (2017) Homeostatic immunity and the microbiota. Immunol. Rev. 262, 562-570
53. Dickson, R.P. (2016) The microbiome and critical illness. Lancet Respir. Med. 4, 59–72
54. Zuo, T. et al. (2020) Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159, 944–955.e648
55. Mohammad, S. and Thiemermann, C. (2020) Role of metabolic endotoxins in systemic inflammation and potential interventions. Front. Immunol. 11, 594150
56. Lee, J.H. et al. (2020) Intermittent fasting: physiological implications on outcomes in mice and men. Physiology (Bethesda) 35, 185–195
57. Gill, S. and Panda, S. (2015) A smartphone app reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. Cell Metab. 22, 789–798
58. Wilkinson, M.J. et al. (2020) Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 31, 92–104.e105
59. Gabel, K. et al. (2018) Effects of 8-hour time-restricted feeding on body weight and metabolic disease risk factors in obese adults: a pilot study. Nutr. Healthy Aging 4, 245–253
60. Keshtyus, D. et al. (2019) Adherence to time-restricted feeding and impact on abdominal obesity in primary care patients: results of a pilot study in a pre-post design. Nutrients 11, 2854
61. Climente, S. et al. (2020) Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity. Cell Metab. 32, 360–378.e303
62. Jamshed, H. et al. (2019) Early time-restricted feeding improves 24-hour glucose levels and affects markers of the circadian clock, aging, and autophagy in humans. Nutrients 11, 1234
63. Sutton, E.F. et al. (2018) Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 27, 1212–1213.e1213
64. Kim, Y.H. et al. (2019) Thermogenesis-independent metabolic benefits conferred by isocaloric intermittent fasting in ob/ob mice. Sci. Rep. 9, 2479
65. Kim, K.H. et al. (2017) Intermittent fasting promotes adipose thermogenesis and metabolic homeostasis via VEGF-mediated alternative activation of macrophage. Cell Res. 27, 1503–1526
66. Chais, A. et al. (2014) Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell Metab. 20, 991–1005
67. Solerte, S.B. et al. (2020) Sagittaplatin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. Diabetes Care 43, 2999–3006
68. Mirani, M. et al. (2020) Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy, Italy. Diabetes Care 43, 3040–3049
69. Deacon, C.F. (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front. Endocrinol. (Lausanne) 10, 80
70. Dogan, S. et al. (2017) The influence of different calorie restriction protocols on serum pro-inflammatory cytokines, adipsokines and IGF-I levels in female C57BL6 mice: short term and long term diet effects. Meta Gene 12, 22–32
71. Fatt, M.A. et al. (2012) Intermittent fasting during Ramadan attenuates proinflammatory cytokines and immune cells in healthy subjects. Nutr. Res. 32, 947–965
72. Almennessier, A.S. et al. (2019) The effects of daily intermittent fasting on proinflammatory cytokine levels while controlling for sleep/wake pattern, meal composition and energy expenditure. PLoS One 14, e026034
73. Ognarela, F. et al. (2018) Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 27, 1222–1235.e1258
